Literature DB >> 21654742

New drug targets for the treatment of obesity.

A G Powell1, C M Apovian, L J Aronne.   

Abstract

There is a huge void in the current pharmacological treatment options for obesity. This gap is surprising given the high prevalence and associated costs of obesity. Many factors have prevented active drug development, including the poor safety and efficacy of earlier antiobesity drugs. However, there are now several compelling targets on the horizon. The new generation of antiobesity drugs offers hope for the management of obesity, but no single agent is likely to be a panacea. Rather, obesity will need to be managed like many other chronic diseases, with combination therapies and long-term treatment in order to achieve sustained success. New targets have arisen as more research has been performed to understand the complex circuitry that controls energy homeostasis. The goal of this review is to discuss the latest pharmacological agents and strategies that are under development and that may eventually be used for the treatment of obesity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21654742     DOI: 10.1038/clpt.2011.82

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  36 in total

1.  Obesity, a health burden of a global nature.

Authors:  Zhi-yun Zhang; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

Review 2.  Gut hormones: the future of obesity treatment?

Authors:  Anne K McGavigan; Kevin G Murphy
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 3.  Potential use of exenatide for the treatment of obesity.

Authors:  Franco Folli; Rodolfo Guardado Mendoza
Journal:  Expert Opin Investig Drugs       Date:  2011-10-24       Impact factor: 6.206

4.  The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.

Authors:  Anita Chawla; Ginger Carls; Edmund Deng; Edward Tuttle
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

5.  Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.

Authors:  Mayank Kumar Sharma; Prashant R Murumkar; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-07-17       Impact factor: 2.943

Review 6.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

7.  Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.

Authors:  Guy A Higgins; Leo B Silenieks; Everett B Altherr; Cam MacMillan; Paul J Fletcher; Wayne E Pratt
Journal:  Psychopharmacology (Berl)       Date:  2016-05-30       Impact factor: 4.530

8.  Obesity and cardiovascular disease.

Authors:  Caroline M Apovian; Noyan Gokce
Journal:  Circulation       Date:  2012-03-06       Impact factor: 29.690

9.  Effect of surfactant hydrophobicity on the pathway for unfolding of ubiquitin.

Authors:  Bryan F Shaw; Grégory F Schneider; George M Whitesides
Journal:  J Am Chem Soc       Date:  2012-10-31       Impact factor: 15.419

10.  Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.

Authors:  Da Xiao; Deshi Shi; Dongfang Yang; Benjamin Barthel; Tad H Koch; Bingfang Yan
Journal:  Biochem Pharmacol       Date:  2012-12-07       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.